Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by bealerton Feb 17, 2024 5:27pm
125 Views
Post# 35886166

RE:RE:Revenue forecast

RE:RE:Revenue forecastThe extrapolation sounds great.  I think waiting until 1st quarter of 25 is a bit slow.  They must be able to get at least some advance product out there before that.  Why should we have to wait another year after we have already waited over 16 years for this thing to get some wheels?

About the bonus shares that Howhee received:  Are these free to him for backing the loan?  If so, that is no wonder we are at 'almost nowheresville' at this time.  Maybe I'm reading this wrong but he has only advanced 540K on the loan to date but still got to take all 450k shares.  He should be made to wait until he has loaned the full million before he is eligible to get all 450K shares, wouldn't one think?

I hope I'm reading this wrong but it wouldn't surprise me at all if he got a HUGE advantage for the loan.  That would keep things consistent at least.

Any comments??

BeAlert




<< Previous
Bullboard Posts
Next >>